Core Viewpoint - COSCIENS Biopharma Inc. held its annual general and special meeting of shareholders, where key voting results were announced, including the election of directors and the appointment of auditors [1][2]. Voting Results - Peter H. Puccetti was elected as Chair with 580,289 votes for (88.92%) and 72,286 votes against (11.08%) [2] - Anthony J. Giovinazzo received 574,954 votes for (88.11%) and 77,621 votes against (11.89%) [2] - Ulrich Kosciessa garnered 580,140 votes for (88.90%) and 72,435 votes against (11.10%) [2] - Ronald W. Miller was elected with 448,646 votes for (68.75%) and 203,929 votes against (31.25%) [2] - Robert A. Seager received 580,254 votes for (88.92%) and 72,321 votes against (11.08%) [2] - David Spear had 580,106 votes for (88.89%) and 72,469 votes against (11.11%) [2] - Deloitte LLP was appointed as the Company's auditor [2] - An ordinary resolution to approve the Company's Amended and Restated Shareholder Rights Plan was also approved [2]. Company Overview - COSCIENS Biopharma Inc. is a life sciences company focused on developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical, and pharmaceutical products [5]. - The company utilizes proprietary extraction technology for producing active ingredients from renewable plant resources, which are used in leading skincare brands [5]. - The portfolio includes macimorelin (Macrilen; Ghryvelin), the first and only FDA and EMA approved oral test for diagnosing adult growth hormone deficiency [5]. Listing Information - COSCIENS is listed on both the NASDAQ Capital Market and the Toronto Stock Exchange under the ticker symbol "CSCI" [6].
COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders